Vittorio Luigi Garosi

Author

Bayer (Germany)

Also Known As

V Garosi, V L Garosi, V. Garosi, Vittorio Garosi, Vittorio L. Garosi, Vittorio Luigi Garosi

Publications

278

Citations

H-Index

Concepts

All Affiliations

Bayer (Germany)Bayer (Italy)Antwerp University Hospital Palacký University Olomouc University of Colorado Denver

About

Vittorio Luigi Garosi is an author at Bayer (Germany) specializing in medicine, pharmacology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	249
2	Health Sciences	1	1	18
3	Diabetes	1	1	13
4	Geriatrics	1	1	13
5	Hepatology	1	1	18

Vittorio Luigi Garosi

Publications

249

Citations

H-Index

Page 1

	Year	Citations
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer Jean‐Luc Van Laethem, Hanno Riess, Jacek Jassem, Targeted Oncology Pancreatic CancerGastrointestinal OncologyPhase I/ii StudyMedicinePharmacology	2016	60
Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial Guillem Argilés, Mark Saunders, Fernando Rivera, European Journal of Cancer Modified Folfox6Gastrointestinal OncologyMedicinePharmacologyColorectal Cancer	2015	53
Efficacy and tolerability of moclobemide in bulimia nervosa: a placebo-controlled trial Michele O. Carruba, Massimo Cuzzolaro, Laura Riva, International Clinical Psychopharmacology ObesityNutritionHypertensionNon-pharmacological InterventionPsychiatry	2001	52
Effect of medroxyprogesterone acetate on the quality of life of the oncologic patient B Neri, Vittorio Luigi Garosi, Claudio Intini Anti-Cancer Drugs Medroxyprogesterone AcetateMegestrol AcetateOncologyWeight LossCancer Management	1997	31
Updated results of a phase 1b study of regorafenib (REG) 80 mg/day or 120 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC). Anthony B. El-Khoueiry, Richard D. Kim, William Proctor Harris, Journal of Clinical Oncology First-line TreatmentPharmacotherapyImmunotherapyReg DosePre-clinical Pharmacology	2021	18
Central nervous system involvement in elderly patients with non-insulin-dependent diabetes mellitus Massimo Cerizza, Giuseppe Minciotti, Stefania Meregalli, Acta Diabetologica AgingElderly PatientsGeriatricsMedicineDementia	1990	13
Phase II study of refametinib (BAY 86-9766), an allosteric dual MEK 1/2 inhibitor, and gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer. Jean‐Luc Van Laethem, Jacek Jassem, Volker Heinemann, Journal of Clinical Oncology PathologyPhase Ii StudyBay 86-9766Metastatic Pancreatic CancerKras Subgroups	2014	12
Pharmacological antagonism of lipoprivic feeding induced by sodium mercaptoacetate Vittorio Luigi Garosi, Enzo Nisoli, John E. Blundell, European Journal of Pharmacology Lipid NutritionMedicineToxicologyMetabolismPharmacology	1995	10

Page 1